Iniparib

SKU: orb1300963

Description

Iniparib (BSI-201) is a potent PARP1 inhibitor used in research, particularly for studying triple-negative breast cancer (TNBC). It is applied in both in vitro and in vivo experimental models to investigate mechanisms of DNA repair and potential therapeutic strategies.

Research Area

Epigenetics & Chromatin, Infectious Disease & Virology, Molecular Biology

Key Properties

• CAS Number: 160003-66-7
• MW: 292.03
• Purity: >98%
• Formula: C₇H₅IN₂O₃
• SMILES: N(=O)(=O)C1=CC(C(N)=O)=CC=C1I
• Target: PARP
• Solubility: Soluble in DMSO (up to 15 mg/ml), or in Ethanol (up to 15 mg/ml).

Bioactivity

• In Vivo:
  In 855-2 cells, the combination of BSI-201 (120 μM) and buthionine sulfoximine induced cell death up to 95%, which was similar to the effect on other human tumor cells. In E-ras 20 cells, BSI-201 inhibited cell growth, and its effect was enhanced 20-fold when combined with buthionine sulfoximine. BSI-201 (100 μM) inhibited the repair of ionizing radiation-induced single-strand breaks (SSBs) in human lymphocyte cell lines.
• Cell Research:
  Cells are exposed to various concentrations of BSI-201 for 5, and 9 days in the presence or absence of buthionine sulfoxamide (BSO). After treatment, cell proliferation is measured by CellTiter-Glo assay.(Only for Reference)

Storage & Handling

• Storage: RT
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

BSI-201

Compound Identifiers

PubChem CID

9796068